Published: 9 June 2020
Author(s): Keren Marks-Garber, Tali Bdolah-Abram, Samir Nusair
Section: Original article

Idiopathic Pulmonary Fibrosis (IPF), a progressively destructive lung disease caused by unchecked fibroblast activity and uncontrolled formation of pulmonary scar tissue,[1] has a median survival from the time of diagnosis, just short of 3 years. The recently approved anti-fibrotic drugs, pirfenidone and nintedanib, are effective in altering disease progression.[2,3] Therefore, increasing clinical awareness and earlier detection of the disease process have become important goals to achieve.[4] Currently, no useful clinical tools exist for the efficient screening and early detection of IPF.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.